Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | LCAT | P04180 | 1/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | C1S | P09871 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL550020 | 1.00 | NOTUM (0.43) | NOTUMHSD11B1NSD2DRD2DRD3 | |
| SCHEMBL549794 | 1.00 | NOTUM (0.43) | NOTUMHSD11B1NSD2DRD2DRD3 | |
| SCHEMBL550019 | 1.00 | NOTUM (0.43) | NOTUMHSD11B1NSD2DRD2DRD3 | |
| SCHEMBL549793 | 1.00 | NOTUM (0.43) | NOTUMHSD11B1NSD2DRD2DRD3 | |
| SCHEMBL2698132 | 1.00 | NOTUM (0.43) | NOTUMHSD11B1NSD2DRD2DRD3 | |
| SCHEMBL550337 | 0.87 | HSD11B1 (0.43) | HSD11B1LCATKCNJ1FASN | |
| SCHEMBL550338 | 0.87 | HSD11B1 (0.43) | HSD11B1LCATKCNJ1FASN | |
| SCHEMBL2699554 | 0.85 | HSD11B1 (0.38) | HSD11B1DRD2DRD3HCRTR1HCRTR2 | |
| SCHEMBL551056 | 0.85 | HSD11B1 (0.38) | HSD11B1DRD2DRD3HCRTR1HCRTR2 | |
| SCHEMBL551055 | 0.85 | HSD11B1 (0.38) | HSD11B1DRD2DRD3HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2450351-A1 | Lactam compounds and their use as pharmaceuticals | Incyte Corporation (US) | 2012-05-09 | — | — | EP | claimed |
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-01 | — | — | US | claimed |
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2450351-A1 | Lactam compounds and their use as pharmaceuticals | Incyte Corporation (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | HSD11B1, HSD11B2, HSD17B1 | NOTUM 654/4885HSD11B1 1/4885NSD2 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.